Answers are grounded in this paper and cite their sources.
CD19-targeted CAR T-cell therapy (CAR-T) has transformed treatment for elderly patients with relapsed or refractory large B-cell lymphoma (rrLBCL), yet data on its safety and efficacy in octogenarians (aged ≥80 years) often with more comorbidities and frailty remain limited. In this single-institution retrospective study, 24 octogenarians were identified and matched with 48 patients aged 65-79 years receiving standard-of-care CAR-T using 2:1 propensity score matching. Baseline characteristics were similar, except for more use of lisocabtagene maraleucel and tisagenlecleucel (P<0.001) and bridging therapy (P=0.024) in the octogenarian cohort. Median follow-up was 15.8 and 36.7 months for the octogenarian and comparator cohorts, respectively. The octogenarian cohort had a higher rate of grade ≥3 immune effector cell-associated neurotoxicity syndrome (ICANS) (25% vs 21%; age treatment effect (ATE) P=0.027). Among those experiencing grade ≥3 cytokine release syndrome (CRS) or ICANS, hospital stays were significantly longer in the octogenarian cohort (30 days vs. 16 days, ATE P<0.001). CAR T-cell expansion was reduced in octogenarians, with lower peak counts (ATE P=0.038) and expansion over 28 days post-infusion (ATE P<0.01). Overall and complete response rates were comparable between cohorts. Six- and 12-month progression-free survival rates in octogenarians were 57% and 45%, and overall survival rates were 88% and 81%, respectively, with no significant differences from those of the comparator cohort. These findings suggest that selected octogenarians tolerate and benefit from CAR T-cell therapy and underscore the need for strategies to mitigate severe toxicities through close monitoring and supportive care.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.